PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
PYC Therapeutics Ltd 주요 수익원은 Banking and Related Activities이며, 최신 수익 발표에서 수익은 18,735,887입니다. 지역별로는 United States이 PYC Therapeutics Ltd의 주요 시장이며, 수익은 18,735,887입니다.
PYC Therapeutics Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 PYC Therapeutics Ltd의 순손실은 $0입니다.